Syros Pharmaceuticals, Inc. SYRS
0.00 USD 0.00 (+0.00%)
At closeOct 30, 2026, 5:00 PM EDT
0.11 +0.11 +26,700.00%
After hours · Oct 30, 5:00 PM ET
0.0005 Day range 0.0005
0.0001 52-week range 0.02
- YTD
- +14.29%
- 1 year
- 0.00%
News
defenseworld.net Critical Analysis: Syros Pharmaceuticals (NASDAQ:SYRS) & ADVANZ PHARMA (OTCMKTS:CXRXF) Institutional and Insider Ownership 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by insiders. Strong institutional…
defenseworld.net Cyclacel Pharmaceuticals (NASDAQ:BGMS) vs. Syros Pharmaceuticals (NASDAQ:SYRS) Head to Head Analysis Syros Pharmaceuticals (NASDAQ: SYRS - Get Free Report) and Cyclacel Pharmaceuticals (NASDAQ: BGMS - Get Free Report) are both small-cap medical companies, but which is the better stock? We will…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com US Stocks Likely To Open Higher As Wall Street Watches Trump Tariff Talks: 'March, April, May Tend To Be Solid Months In Post-Election Years,' Says Expert US. stock futures rose on Monday following Friday's advances. Futures of all fourth benchmark indices rose in premarket trading.
businesswire.com Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the “Company”) today announced that its Board of Directors (the “Board”) has approved and the Company intends to proceed…
zacks.com Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
benzinga.com Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default Syros Pharmaceuticals Inc SYRS revealed on Tuesday that the SELECT-MDS-1 Phase 3 trial of tamibarotene did not meet its primary endpoint of complete response rate.
benzinga.com Why Rocket Lab Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket 
businesswire.com Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic…
accesswire.com The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros…
accesswire.com Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros…
accesswire.com The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros…
seekingalpha.com Syros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call Transcript Syros Pharmaceuticals, Inc (NASDAQ:SYRS ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Karen Hunady - Director of Investor Relations and Corporate Communications…
businesswire.com Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic…
accesswire.com Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros…
accesswire.com The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros…
businesswire.com Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic…
accesswire.com Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / October 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros…
accesswire.com Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Impacted Shareholders Are Encouraged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / October 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros…
accesswire.com The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros…
accesswire.com Syros Pharmaceuticals Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros…
accesswire.com The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations LOS ANGELES, CA / ACCESSWIRE / October 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros…
accesswire.com Syros Pharmaceuticals Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / October 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros…
benzinga.com Crude Oil Down 2%; Paysafe Shares Surge After Q2 Results - benzinga.com S&P 500 Gains 1%; Home Depot Earnings Top Views
- benzinga.com Nasdaq Surges 200 Points; US Producer Prices Increase 0.1% In July
- benzinga.com Why Rumble Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
- benzinga.com Crude Oil Down Over 1%; Cognyte Software Shares Plummet U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.4% on Tuesday. The Dow traded down 0.46% to 38,713.72 while the NASDAQ fell 0.24% to 16,215.32. The S&P 500 also…
benzinga.com Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Earnings Scheduled For March 27, 2024 Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.- benzinga.com Earnings Scheduled For November 14, 2023 Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.
- benzinga.com Earnings Scheduled For August 8, 2023 Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly earnings at $0.21 per share on revenue of $1.48 billion.
- benzinga.com Earnings Scheduled For May 10, 2023 Companies Reporting Before The Bell • Nomad Foods (NYSE:NOMD) is projected to report quarterly earnings at $0.42 per share on revenue of $851.81 million.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 93 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 198 companies hit new 52-week lows.
benzinga.com Earnings Scheduled For March 2, 2023 Companies Reporting Before The Bell • argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue of $176.89 million.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 298 companies achieved new lows for the year.
benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 297 companies reached new 52-week lows.- benzinga.com Earnings Scheduled For November 14, 2022 Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday morning, 446 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday Thursday saw 177 companies set new 52-week lows.
- benzinga.com Grenwich LilfeSciences, Blue Apron And 3 More Short Squeeze Candidates That May Soar Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move. Here’s a look at the top five short squeeze candidates for the week…
- benzinga.com 10 Short Squeeze Candidates That May Soar: Minerva Neurosciences, FaZe, Getty Images And More Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move.
- benzinga.com Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday.